These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia. Gelsinger C; Steinhagen-Thiessen E; Kassner U Drugs; 2012 Jul; 72(11):1445-55. PubMed ID: 22799743 [TBL] [Abstract][Full Text] [Related]
26. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Della Badia LA; Elshourbagy NA; Mousa SA Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571 [TBL] [Abstract][Full Text] [Related]
27. Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia. Baum SJ; Soffer D; Barton Duell P Rev Cardiovasc Med; 2016; 17(1-2):16-27. PubMed ID: 27667377 [TBL] [Abstract][Full Text] [Related]
28. Novel pharmacological treatments for children and adolescents with heterozygous familial hypercholesterolemia. Wiegman A; Hutten BA Expert Rev Clin Pharmacol; 2017 Sep; 10(9):919-921. PubMed ID: 28756723 [No Abstract] [Full Text] [Related]
29. Preventing early cardiovascular death in patients with familial hypercholesterolemia. Repas TB; Tanner JR J Am Osteopath Assoc; 2014 Feb; 114(2):99-108. PubMed ID: 24481802 [TBL] [Abstract][Full Text] [Related]
31. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Robinson JG J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430 [TBL] [Abstract][Full Text] [Related]
32. Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents. Tada H; Takamura M; Kawashiri MA Vasc Health Risk Manag; 2021; 17():59-67. PubMed ID: 33628029 [TBL] [Abstract][Full Text] [Related]
36. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. Agabiti Rosei E; Salvetti M High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901 [TBL] [Abstract][Full Text] [Related]
37. Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Blom DJ; Averna MR; Meagher EA; du Toit Theron H; Sirtori CR; Hegele RA; Shah PK; Gaudet D; Stefanutti C; Vigna GB; Larrey D; Bloedon LT; Foulds P; Rader DJ; Cuchel M Circulation; 2017 Jul; 136(3):332-335. PubMed ID: 28716835 [No Abstract] [Full Text] [Related]
38. Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab. Tanaka A; Inaguma D; Watanabe Y; Ito E; Kamegai N; Shimogushi H; Shinjo H; Koike K; Otsuka Y; Takeda A Intern Med; 2017; 56(12):1531-1535. PubMed ID: 28626179 [TBL] [Abstract][Full Text] [Related]
39. JCL roundtable: drug treatment of severe forms of familial hypercholesterolemia. Brown WV; Rader DJ; Goldberg AC J Clin Lipidol; 2014; 8(1):10-7. PubMed ID: 24528683 [TBL] [Abstract][Full Text] [Related]
40. Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review. Neef D; Berthold HK; Gouni-Berthold I Expert Rev Clin Pharmacol; 2016; 9(5):655-63. PubMed ID: 26943823 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]